JP2007537220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537220A5 JP2007537220A5 JP2007512327A JP2007512327A JP2007537220A5 JP 2007537220 A5 JP2007537220 A5 JP 2007537220A5 JP 2007512327 A JP2007512327 A JP 2007512327A JP 2007512327 A JP2007512327 A JP 2007512327A JP 2007537220 A5 JP2007537220 A5 JP 2007537220A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- cetirizine
- acid
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 73
- 150000002632 lipids Chemical class 0.000 claims description 20
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 20
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 15
- 229960001803 cetirizine Drugs 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 9
- 239000000872 buffer Substances 0.000 claims 8
- 239000002502 liposome Substances 0.000 claims 7
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 6
- 229930186217 Glycolipid Natural products 0.000 claims 6
- 239000007864 aqueous solution Substances 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000012736 aqueous medium Substances 0.000 claims 4
- 239000007853 buffer solution Substances 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 3
- 239000002585 base Substances 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims 2
- QZXMUPATKGLZAP-DXLAUQRQSA-N [(2S)-1-hexadecanoyloxy-3-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QZXMUPATKGLZAP-DXLAUQRQSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 239000008365 aqueous carrier Substances 0.000 claims 2
- 229910052786 argon Inorganic materials 0.000 claims 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 238000001125 extrusion Methods 0.000 claims 2
- 150000002339 glycosphingolipids Chemical class 0.000 claims 2
- 238000000265 homogenisation Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 238000010979 pH adjustment Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 239000003755 preservative agent Substances 0.000 claims 2
- 230000002335 preservative effect Effects 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 238000007670 refining Methods 0.000 claims 2
- 238000005096 rolling process Methods 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 239000002562 thickening agent Substances 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 1
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- IJFVSSZAOYLHEE-UHFFFAOYSA-N 2,3-di(dodecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-UHFFFAOYSA-N 0.000 claims 1
- OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 claims 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims 1
- 239000005711 Benzoic acid Substances 0.000 claims 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 claims 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 229910002651 NO3 Inorganic materials 0.000 claims 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- DSNRWDQKZIEDDB-GCMPNPAFSA-N [(2r)-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C/CCCCCCCC DSNRWDQKZIEDDB-GCMPNPAFSA-N 0.000 claims 1
- 239000008351 acetate buffer Substances 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 229940087168 alpha tocopherol Drugs 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- 235000010233 benzoic acid Nutrition 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical group [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 1
- 229940067596 butylparaben Drugs 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 150000003841 chloride salts Chemical group 0.000 claims 1
- 229960004926 chlorobutanol Drugs 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 229960004106 citric acid Drugs 0.000 claims 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims 1
- 235000019797 dipotassium phosphate Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims 1
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 claims 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 229960002598 fumaric acid Drugs 0.000 claims 1
- 235000011087 fumaric acid Nutrition 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000001630 malic acid Substances 0.000 claims 1
- 235000011090 malic acid Nutrition 0.000 claims 1
- 229940099690 malic acid Drugs 0.000 claims 1
- 238000010907 mechanical stirring Methods 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 229960003330 pentetic acid Drugs 0.000 claims 1
- 229960005323 phenoxyethanol Drugs 0.000 claims 1
- 229940067107 phenylethyl alcohol Drugs 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 150000003905 phosphatidylinositols Chemical class 0.000 claims 1
- 235000011007 phosphoric acid Nutrition 0.000 claims 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 claims 1
- 229940043349 potassium metabisulfite Drugs 0.000 claims 1
- 235000010263 potassium metabisulphite Nutrition 0.000 claims 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 229940095574 propionic acid Drugs 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 235000010388 propyl gallate Nutrition 0.000 claims 1
- 229940075579 propyl gallate Drugs 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- 229940001607 sodium bisulfite Drugs 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 claims 1
- 229940001584 sodium metabisulfite Drugs 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229940001482 sodium sulfite Drugs 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 238000003260 vortexing Methods 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/842,433 | 2004-05-11 | ||
| US10/842,433 US20050255154A1 (en) | 2004-05-11 | 2004-05-11 | Method and composition for treating rhinitis |
| PCT/GB2005/001758 WO2005107711A2 (en) | 2004-05-11 | 2005-05-06 | Method and composition for treating rhinitis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007537220A JP2007537220A (ja) | 2007-12-20 |
| JP2007537220A5 true JP2007537220A5 (enExample) | 2008-06-19 |
| JP4976283B2 JP4976283B2 (ja) | 2012-07-18 |
Family
ID=34968224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512327A Expired - Fee Related JP4976283B2 (ja) | 2004-05-11 | 2005-05-06 | 鼻炎の治療方法及び組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20050255154A1 (enExample) |
| EP (1) | EP1771155B1 (enExample) |
| JP (1) | JP4976283B2 (enExample) |
| CN (2) | CN1984643A (enExample) |
| AT (1) | ATE550015T1 (enExample) |
| AU (1) | AU2005239866B2 (enExample) |
| BR (1) | BRPI0510778B8 (enExample) |
| CA (1) | CA2536728C (enExample) |
| CY (1) | CY1112981T1 (enExample) |
| DK (1) | DK1771155T3 (enExample) |
| EA (1) | EA014752B1 (enExample) |
| ES (1) | ES2395130T3 (enExample) |
| HR (1) | HRP20120484T1 (enExample) |
| IL (1) | IL179012A (enExample) |
| ME (1) | ME01436B (enExample) |
| MX (1) | MXPA06013121A (enExample) |
| NO (1) | NO335840B1 (enExample) |
| NZ (1) | NZ550412A (enExample) |
| PL (1) | PL1771155T3 (enExample) |
| PT (1) | PT1771155E (enExample) |
| RS (1) | RS52311B (enExample) |
| SI (1) | SI1771155T1 (enExample) |
| WO (1) | WO2005107711A2 (enExample) |
| ZA (1) | ZA200608407B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20060484A1 (es) | 2004-07-14 | 2006-07-06 | Ucb Farchim Sa | Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina |
| US20090220583A1 (en) | 2005-06-09 | 2009-09-03 | Lena Pereswetoff-Morath | Method and composition for treating inflammatory disorders |
| FR2900576B1 (fr) * | 2006-05-03 | 2008-09-19 | Centre Nat Rech Scient | Procede de concentration extemporanee et reversible de liposomes. |
| US20090269393A1 (en) * | 2006-06-12 | 2009-10-29 | Jubliant Organosys Limited | Chewable Bilayer Tablet Formulation |
| AU2008326800A1 (en) * | 2007-11-16 | 2009-05-28 | Baylor College Of Medicine | Phospholipid compositions and uses thereof |
| WO2009148955A2 (en) * | 2008-05-29 | 2009-12-10 | Mdrna, Inc | Multi-arm amines and uses thereof |
| US8569273B2 (en) | 2009-03-17 | 2013-10-29 | Aciex Therapeutics, Inc. | Ophthalmic formulations of cetirizine and methods of use |
| ES2910374T3 (es) | 2009-03-17 | 2022-05-12 | Nicox Ophthalmics Inc | Formulaciones oftálmicas de cetirizina y procedimientos de uso |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| US8513259B2 (en) | 2009-07-03 | 2013-08-20 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| US8524692B2 (en) * | 2010-04-29 | 2013-09-03 | Georgia Health Sciences University Research Institute, Inc. | Ocular compositions containing dioleoylphosphatidylglycerol and uses thereof |
| WO2012013566A1 (en) * | 2010-07-28 | 2012-02-02 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and inflammatory diseases |
| CN102525921B (zh) * | 2012-02-06 | 2013-08-07 | 西安力邦制药有限公司 | 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法 |
| KR101475776B1 (ko) * | 2012-08-24 | 2014-12-24 | 영진약품공업 주식회사 | 이중 포화 인지질을 포함하는 안정한 피부 외용 조성물 |
| CN104887635B (zh) * | 2015-05-20 | 2019-06-11 | 苏州东瑞制药有限公司 | 一种盐酸西替利嗪片及其制备工艺 |
| CN113434592A (zh) * | 2018-10-31 | 2021-09-24 | 创新先进技术有限公司 | 基于区块链的数据存证方法及装置、电子设备 |
| US20220395438A1 (en) * | 2019-11-04 | 2022-12-15 | Universitat Autonoma De Barcelona | Tooth whitening composition |
| CN114392235B (zh) * | 2022-01-28 | 2023-06-27 | 成都大学 | 盐酸西替利嗪眼用脂质体、原位凝胶及其制备方法 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1523965A (en) * | 1976-03-19 | 1978-09-06 | Ici Ltd | Pharmaceutical compositions containing steroids |
| US5141674A (en) * | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| US5374548A (en) * | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| GB8522964D0 (en) | 1985-09-17 | 1985-10-23 | Biocompatibles Ltd | Aerosol |
| AU7543887A (en) | 1986-06-12 | 1988-01-11 | Liposome Company, Inc., The | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| CA1320130C (en) | 1986-06-12 | 1993-07-13 | Alan L. Weiner | Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs |
| US4839175A (en) * | 1986-07-28 | 1989-06-13 | Liposome Technology, Inc. | Liposomes with enhanced retention on mucosal tissue |
| SE8603812D0 (sv) | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
| US5049388A (en) * | 1986-11-06 | 1991-09-17 | Research Development Foundation | Small particle aerosol liposome and liposome-drug combinations for medical use |
| US5422120A (en) * | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| EP0472639A4 (en) | 1989-05-15 | 1992-07-01 | The Liposome Company, Inc. | Accumulation of drugs into liposomes by a proton gradient |
| US5498420A (en) * | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
| US5773457A (en) * | 1995-02-15 | 1998-06-30 | Cesar Roberto Dias Nahoum | Compositions |
| TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
| WO1995013796A1 (en) * | 1993-11-16 | 1995-05-26 | Depotech Corporation | Vesicles with controlled release of actives |
| DE4341472A1 (de) | 1993-12-02 | 1995-06-08 | Schering Ag | Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen |
| ES2183865T3 (es) * | 1994-02-04 | 2003-04-01 | Lipocore Holding Ab | Preparaciones de doble capa de galactolipido que contienen digalactosildiacilglicerol. |
| US6773719B2 (en) * | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
| NZ294392A (en) * | 1994-09-23 | 1999-05-28 | Axys Pharm Inc | Asthma drugs and compounds |
| WO1997001337A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
| US5783566A (en) * | 1996-05-10 | 1998-07-21 | California Institute Of Technology | Method for increasing or decreasing transfection efficiency |
| JPH11511758A (ja) | 1996-06-04 | 1999-10-12 | ザ、プロクター、エンド、ギャンブル、カンパニー | 鼻腔用ステロイドと抗ヒスタミン剤を含む鼻腔内噴霧薬 |
| US5958378A (en) | 1996-07-03 | 1999-09-28 | Research Development Foundation | High dose liposomal aerosol formulations containing cyclosporin A or budesonide |
| TW497974B (en) | 1996-07-03 | 2002-08-11 | Res Dev Foundation | High dose liposomal aerosol formulations |
| GB9625589D0 (en) * | 1996-12-10 | 1997-01-29 | Boots Co Plc | Therapeutic agents |
| WO1998048839A1 (en) | 1997-04-30 | 1998-11-05 | Warner-Lambert Company | Topical nasal antiinflammatory compositions |
| GB2326337A (en) | 1997-06-20 | 1998-12-23 | Phares Pharma Holland | Homogeneous lipid compositions for drug delivery |
| JP2002507917A (ja) * | 1997-07-04 | 2002-03-12 | トルサナ オステオポロシス ダイアグノスティクス アクティーゼルスカブ | 脊椎動物の骨質又は骨格状態を評価するための方法 |
| BR9816113A (pt) * | 1998-12-23 | 2001-10-23 | Idea Ag | Formulação aperfeiçoada para aplicação tópica não-invasiva in vivo |
| GR1003359B (el) | 1998-12-24 | 2000-04-10 | �.�. ����������� �.�.�.�. | Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου |
| US6613352B2 (en) * | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
| US20030124180A1 (en) * | 2000-05-02 | 2003-07-03 | Jurgen Ebert | Liposomes containing active substances |
| ES2260321T3 (es) | 2000-12-07 | 2006-11-01 | Universiteit Utrecht Holding B.V. | Composicion para el tratamiento de transtornos inflamatorios. |
| US20030144336A1 (en) * | 2001-08-27 | 2003-07-31 | Pfizer Inc. | Method of selecting nonsedating H1-antagonists |
| US20030054030A1 (en) * | 2001-09-13 | 2003-03-20 | Gary Gordon | Method and compositions for the treatment of pruritus |
| DE60209154T2 (de) | 2001-12-05 | 2006-08-10 | Alcon Inc. | Verwendung eines h1-antagonisten und eines sicheren steroids zur behandlung einer rhinitis |
| AU2003252187A1 (en) | 2002-05-15 | 2003-12-02 | Engelbrecht, Edna | Topical composition for the treatment of inflammatory conditions of the skin |
| EP1371362A1 (en) | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
| US20040192601A1 (en) * | 2002-08-02 | 2004-09-30 | Silvia Corvera | Lipid binding molecules and methods of use |
| JP2004168709A (ja) * | 2002-11-20 | 2004-06-17 | Nidek Co Ltd | 抗アレルギー点眼点鼻用組成物 |
| WO2004069338A1 (en) * | 2003-01-31 | 2004-08-19 | Schering Corporation | Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions |
| US20050112199A1 (en) * | 2003-09-24 | 2005-05-26 | Mahesh Padval | Therapeutic regimens for administering drug combinations |
| AU2004283464B8 (en) | 2003-10-15 | 2011-04-14 | Syncore Biotechnology Co., Ltd | Method of administering cationic liposomes comprising an active drug |
| JP2005170923A (ja) * | 2003-10-21 | 2005-06-30 | Konica Minolta Medical & Graphic Inc | リポソーム含有ｘ線造影剤およびその製造方法 |
-
2004
- 2004-05-11 US US10/842,433 patent/US20050255154A1/en not_active Abandoned
-
2005
- 2005-05-06 CN CNA2005800153171A patent/CN1984643A/zh active Pending
- 2005-05-06 RS RS20120246A patent/RS52311B/sr unknown
- 2005-05-06 WO PCT/GB2005/001758 patent/WO2005107711A2/en not_active Ceased
- 2005-05-06 DK DK05742190.1T patent/DK1771155T3/da active
- 2005-05-06 HR HRP20120484TT patent/HRP20120484T1/hr unknown
- 2005-05-06 AU AU2005239866A patent/AU2005239866B2/en not_active Ceased
- 2005-05-06 BR BRPI0510778A patent/BRPI0510778B8/pt not_active IP Right Cessation
- 2005-05-06 ZA ZA200608407A patent/ZA200608407B/xx unknown
- 2005-05-06 NZ NZ550412A patent/NZ550412A/en not_active IP Right Cessation
- 2005-05-06 EA EA200602092A patent/EA014752B1/ru unknown
- 2005-05-06 ME MEP-2012-77A patent/ME01436B/me unknown
- 2005-05-06 ES ES05742190T patent/ES2395130T3/es not_active Expired - Lifetime
- 2005-05-06 EP EP05742190A patent/EP1771155B1/en not_active Expired - Lifetime
- 2005-05-06 JP JP2007512327A patent/JP4976283B2/ja not_active Expired - Fee Related
- 2005-05-06 PL PL05742190T patent/PL1771155T3/pl unknown
- 2005-05-06 SI SI200531529T patent/SI1771155T1/sl unknown
- 2005-05-06 US US10/571,330 patent/US20070026058A1/en not_active Abandoned
- 2005-05-06 PT PT05742190T patent/PT1771155E/pt unknown
- 2005-05-06 MX MXPA06013121A patent/MXPA06013121A/es active IP Right Grant
- 2005-05-06 AT AT05742190T patent/ATE550015T1/de active
- 2005-05-06 CA CA2536728A patent/CA2536728C/en not_active Expired - Lifetime
- 2005-05-06 CN CN201310132640.3A patent/CN103271910B/zh not_active Expired - Fee Related
-
2006
- 2006-10-05 NO NO20064521A patent/NO335840B1/no not_active IP Right Cessation
- 2006-11-02 IL IL179012A patent/IL179012A/en active IP Right Grant
-
2012
- 2012-04-11 US US13/444,381 patent/US9980959B2/en active Active
- 2012-06-13 CY CY20121100541T patent/CY1112981T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537220A5 (enExample) | ||
| RU2444351C2 (ru) | Композиция для лечения ринита и родственных заболеваний и способ ее получения | |
| EP1888033B1 (en) | Method and composition for treating inflammatory disorders | |
| CA2536728A1 (en) | Method and composition for treating rhinitis | |
| US20090041835A1 (en) | Method of inhibiting leakage of drug encapsulated in liposomes | |
| US8765181B2 (en) | Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids | |
| US20100178243A1 (en) | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | |
| WO2011066684A1 (zh) | 伊立替康或盐酸伊立替康脂质体及其制备方法 | |
| JP2009507009A5 (enExample) | ||
| CN108366965A (zh) | 稳定喜树碱药物组合物 | |
| EP1393719A1 (en) | Camptothecin-carboxylate formulations | |
| JP6479485B2 (ja) | 眼疾患治療用ナノ粒子製剤 | |
| RU2369384C2 (ru) | Стабильные липосомальные композиции | |
| US20250313531A1 (en) | Formulated and/or Co-Formulated Liposome Compositions Containing IDO Antagonist Prodrugs Useful in the Treatment of Cancer and Methods Thereof | |
| JP6230538B2 (ja) | 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法 | |
| JPH07507542A (ja) | 負の過剰電荷を有するリポソーム | |
| WO2005092388A1 (ja) | リポソーム製剤 | |
| CN1240348A (zh) | 含一种醚类脂/互补形类脂混合物的载体和其治疗用途 | |
| CN1980671B (zh) | 含有水难溶性喜树碱的脂质体制剂 | |
| JP2019525922A (ja) | 癌を治療するための方法および組成物 | |
| US20230226031A1 (en) | Formulated and/or Co-Formulated Liposome Compositions Containing Immunogenic Cell Death (ICD) Inducing Prodrugs Useful In The Treatment of Cancer and Methods Thereof | |
| US20170071967A1 (en) | Immunogenic liposomal formulation | |
| WO2011037252A1 (ja) | スピカマイシン誘導体を含有するリポソーム製剤 | |
| JPH10505818A (ja) | リポソーム製剤 | |
| JP2001181207A (ja) | 難水溶性薬理活性物質のろ過滅菌可能化方法 |